National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Access to Care (1)
- (-) Cancer (11)
- Cancer: Colorectal Cancer (1)
- Cancer: Lung Cancer (1)
- Cancer: Prostate Cancer (1)
- Diagnostic Safety and Quality (1)
- Disparities (2)
- Elderly (1)
- Genetics (1)
- (-) Healthcare Costs (11)
- Health Information Technology (HIT) (1)
- Health Insurance (2)
- Kidney Disease and Health (1)
- Medical Expenditure Panel Survey (MEPS) (2)
- Medication (3)
- Palliative Care (1)
- Patient-Centered Outcomes Research (3)
- Practice Patterns (1)
- Prevention (1)
- Racial and Ethnic Minorities (2)
- Screening (2)
- Shared Decision Making (2)
- Surgery (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 11 of 11 Research Studies DisplayedRoth JA, Ramsey SD, Carlson JJ
Cost-effectiveness of a biopsy-based 8-protein prostate cancer prognostic assay to optimize treatment decision making in Gleason 3 + 3 and 3 + 4 early stage prostate cancer.
A novel 8-protein prognostic assay generates a risk score at time of biopsy that is predictive of prostate cancer aggressiveness and can inform treatment decisions. The objective of this study was to evaluate the cost-effectiveness of using the assay to inform treatment decisions compared with usual care. The 8-protein assay strategy resulted in 0.04 more quality-adjusted life years and $700 less in costs compared with usual care.
AHRQ-funded; HS022982.
Citation: Roth JA, Ramsey SD, Carlson JJ .
Cost-effectiveness of a biopsy-based 8-protein prostate cancer prognostic assay to optimize treatment decision making in Gleason 3 + 3 and 3 + 4 early stage prostate cancer.
Oncologist 2015 Dec;20(12):1355-64. doi: 10.1634/theoncologist.2015-0214.
.
.
Keywords: Cancer, Cancer: Prostate Cancer, Patient-Centered Outcomes Research, Healthcare Costs, Shared Decision Making
Levy DE, Munshi VN, Ashburner JM
Health IT-assisted population-based preventive cancer screening: a cost analysis.
The researchers analyzed costs from a randomized trial of 2 health IT strategies to improve cancer screening compared with usual care from the perspective of a primary care network. They found that over the course of the study year, the value of reduced physician time devoted to preventive cancer screening outweighed the costs of the interventions.
AHRQ-funded; HS020308; HS018161.
Citation: Levy DE, Munshi VN, Ashburner JM .
Health IT-assisted population-based preventive cancer screening: a cost analysis.
Am J Manag Care 2015 Dec;21(12):885-91..
Keywords: Health Information Technology (HIT), Cancer, Screening, Prevention, Healthcare Costs
Guy GP, Jr., Yabroff KR, Ekwueme DU
AHRQ Author: Soni A
Healthcare expenditure burden among non-elderly cancer survivors, 2008-2012.
This study presented nationally representative estimates of annual out-of-pocket (OOP) burden among non-elderly cancer survivors and assessed the association between high OOP burden and access to care and preventive service utilization. It found that, among cancer survivors, high OOP burden was associated with being unable to obtain necessary medical care, delaying necessary medical care, and lower breast cancer screening rates among women.
AHRQ-authored.
Citation: Guy GP, Jr., Yabroff KR, Ekwueme DU .
Healthcare expenditure burden among non-elderly cancer survivors, 2008-2012.
Am J Prev Med 2015 Dec;49(6s5):S489-s97. doi: 10.1016/j.amepre.2015.09.002.
.
.
Keywords: Medical Expenditure Panel Survey (MEPS), Healthcare Costs, Cancer, Access to Care
Du XL, Parikh RC, Lairson DR
Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab.
The authors examined racial/ethnic and geographical disparities in cancer care and costs during the last 6 months of life for lung cancer decedents after the FDA's approval of bevacizumab. They found that there were substantial racial/ethnic and geographic disparities in the types of cancer care and costs in the last 6 months of life among lung cancer decedents, regardless of the length of survival times and hospice care status.
AHRQ-funded; HS018956.
Citation: Du XL, Parikh RC, Lairson DR .
Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab.
Lung Cancer 2015 Dec;90(3):442-50. doi: 10.1016/j.lungcan.2015.09.017.
.
.
Keywords: Cancer, Cancer: Lung Cancer, Disparities, Healthcare Costs, Medication, Palliative Care, Patient-Centered Outcomes Research, Practice Patterns, Racial and Ethnic Minorities
Shih YC, Smieliauskas F, Geynisman DM
Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011.
This study sought to define and identify drivers of trends in cost and use of targeted therapeutics among privately insured nonelderly patients with cancer receiving chemotherapy between 2001 and 2011. It found a large increase in the use of targeted intravenous anticancer medications and a gradual increase in targeted oral anticancer medications; targeted therapies accounted for 63 percent of all chemotherapy expenditures in 2011.
AHRQ-funded; HS018535; HS020263.
Citation: Shih YC, Smieliauskas F, Geynisman DM .
Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011.
J Clin Oncol 2015 Jul 1;33(19):2190-6. doi: 10.1200/jco.2014.58.2320..
Keywords: Healthcare Costs, Cancer, Health Insurance, Medication
Gallego CJ, Shirts BH, Bennette CS
Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis.
The researchers evaluated the cost effectiveness of next-generation sequencing (NGS) panels for the diagnosis of colorectal cancer and polyposis (CRCP) syndromes in patients referred to cancer genetics clinics. They concluded that the use of an NGS panel that includes genes associated with highly penetrant CRCP syndromes in addition to Lynch syndrome genes as a first-line test is likely to provide meaningful clinical benefits in a cost-effective manner.
AHRQ-funded; HS021686.
Citation: Gallego CJ, Shirts BH, Bennette CS .
Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis.
J Clin Oncol 2015 Jun 20;33(18):2084-91. doi: 10.1200/jco.2014.59.3665..
Keywords: Cancer, Cancer: Colorectal Cancer, Shared Decision Making, Diagnostic Safety and Quality, Genetics, Healthcare Costs, Screening
Vemana G, Vetter J, Chen L
Sources of variation in follow-up expenditure after radical cystectomy.
Follow-up care after radical cystectomy is poorly defined, with extensive variation in practice patterns. The researchers sought to determine sources of these variations in care as well as examine the economic effect of standardization of care on guideline-recommended care. The most variation in expenditure on follow-up care was at the patient level, largely based on node positivity, chemotherapy status, and final cancer stage.
AHRQ-funded; HS019455.
Citation: Vemana G, Vetter J, Chen L .
Sources of variation in follow-up expenditure after radical cystectomy.
Urol Oncol 2015 Jun;33(6):267.e31-7. doi: 10.1016/j.urolonc.2015.03.009..
Keywords: Cancer, Surgery, Healthcare Costs, Elderly
Pisu M, Kenzik KM, Oster RA
Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer?
The authors investigated economic hardships experienced by racial/ethnic minority cancer survivors compared to whites. They found that economic hardship was evident in almost 1 in 2 cancer survivors 1 year after diagnosis, especially African Americans. They recommended that future research evaluate and address risk factors and their impact on survival and survivorship outcomes.
AHRQ-funded; HS013852.
Citation: Pisu M, Kenzik KM, Oster RA .
Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer?
Cancer 2015 Apr 15;121(8):1257-64. doi: 10.1002/cncr.29206.
.
.
Keywords: Cancer, Disparities, Healthcare Costs, Patient-Centered Outcomes Research, Racial and Ethnic Minorities
Conti RM, Padula WV, Larson RA
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
This article discusses various issues associated with potential impact on health system spending levels for chronic myeloid leukemia after generic imatinib becomes available. Included is a review of their implications for the development of country-specific cost-effectiveness models to predict the implications for cost and quality of care from generic imatinib.
AHRQ-funded; HS023710.
Citation: Conti RM, Padula WV, Larson RA .
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Ann Hematol 2015 Apr;94 Suppl 2:S249-57. doi: 10.1007/s00277-015-2319-x..
Keywords: Cancer, Medication, Healthcare Costs
Geynisman DM, Hu JC, Liu L
Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
The researchers used a large claims database to examine the evolution of treatment patterns and associated costs for 1527 metastatic renal cell carcinoma (mRCC) patients in the United States. They found that the treatment of mRCC has transitioned from cytokines and cytotoxic chemotherapy to almost exclusively targeted therapy. Cost of care for mRCC is rising each year, and out-of-pocket costs for patients are significant.
AHRQ-funded; HS018535; HS020263.
Citation: Geynisman DM, Hu JC, Liu L .
Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
Clin Genitourin Cancer 2015 Apr;13(2):e93-100. doi: 10.1016/j.clgc.2014.08.013..
Keywords: Cancer, Kidney Disease and Health, Health Insurance, Healthcare Costs
Guy GP, Machlin SR, Ekwueme DU
AHRQ Author: Machlin SR
Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.
This study examines trends in the treated prevalence and treatment costs of nonmelanoma and melanoma skin cancers. It found that the average annual number of adults treated for any skin cancer (NMSC or melanoma) increased from 3.4 to 4.9 million between 2002-2006 and 2007-2011. In the same period, the average annual total cost for skin cancer increased by 126.2 percent, from $3.6 billion to $8.1 billion.
AHRQ-authored
Citation: Guy GP, Machlin SR, Ekwueme DU .
Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.
Am J Prev Med 2015 Feb;48(2):183-7. doi: 10.1016/j.amepre.2014.08.036..
Keywords: Cancer, Healthcare Costs, Medical Expenditure Panel Survey (MEPS)